(Q41474323)

English

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

scientific article published on 18 August 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christian Thiede

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Gerhard Ehninger

24

object named as

G Ehninger

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Martin Bornhäuser

25

object named as

M Bornhäuser

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Johannes Schetelig

26

object named as

J Schetelig

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Uwe Platzbecker

21

object named as

U Platzbecker

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

R Herbst

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Parmentier

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

G Bug

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Hänel

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

G Stuhler

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

K Schäfer-Eckart

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

W Rösler

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Klein

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

W Bethge

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

U Bitz

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B Büttner

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H Knoth

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Schaich

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Morgner

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Kramer

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

K Sockel

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M von Bonin

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

F Stölzel

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Röllig

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

18 August 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

261-267

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26283567%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2015.226

0 references

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Relapsed acute myeloid leukemia: why is there no standard of care?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

The therapy of relapsed acute leukaemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Treatment for relapsed acute myeloid leukemia: what is new?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

The myth of the second remission of acute leukemia in the adult

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.226

21 January 2018

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correcting 2 more myths regarding transplants for AML in second remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/26283567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41474323&oldid=1526687701"